No-cost study-related care under a doctor’s supervision for a 6 month research study
New research opportunity for dementia: investigational treatment targeting inflammation
Living with dementia?
Have you, or someone you’re caring for, been diagnosed with early dementia or Alzheimer’s? If so, you could qualify to participate in a new study evaluating an investigational dementia treatment.
Apply below to see if you qualify for this 6-month study. All eligible participants will have the opportunity to receive the study drug.
See if you qualify
Fill out the form below to see if you meet the basic study requirements. If you are filling this out on behalf of a friend or loved-one, please enter the information on their behalf but please include YOUR contact phone number for follow up.
What do I need to know?
Frequently asked questions
The goal of this AD study is to determine if the investigational study medication is effective at either improving or slowing disease progression on measures of cognition, functioning and behavior in individuals with early Alzheimer’s disease with biomarkers of inflammation.
Yes, at the end of the full 24-week study period, all eligible participants will have the opportunity to receive the investigational study medication for one year.
The study is approximately 33 weeks long, comprised of an up to 45-day screening period, a 24-week treatment period, and a 28-day follow-up period.
A notable difference in this study versus other investigational studies for Dementia is the short treatment period of 24 weeks. Additionally, the study requires only 9-13 study visits and the drug may be administered at home for a portion of the study period if the patient and/or caregiver prefers.
The study drug is called the XPRO1595 which is administered via a weekly injection.
For this study, the enrolled patient is required to have a “study partner” in order to participate. The Study Partner must be knowledgeable about the patient’s behaviors, routines, and medications with the goal of assisting the participant in meeting study requirements, including co-attending study visits (as few as 9).